| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PKCe |
| Uniprot No | Q02156 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 580-737aa |
| 氨基酸序列 | QELEYGPSVDWWALGVLMYEMMAGQPPFEADNEDDLFESILHDDVLYPVW LSKEAVSILKAFMTKNPHKRLGCVASQNGEDAIKQHPFFKEIDWVLLEQK KIKPPFKPRIKTKRDVNNFDQDFTREEPVLTLVDEAIVKQINQEEFKGFS YFGEDLMP |
| 预测分子量 | 18 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PKCε重组蛋白的3篇参考文献示例(注：文献信息为虚构，仅用于示例格式)：
---
1. **文献名称**：*Recombinant PKCε enhances cell migration through activation of Rho GTPase signaling*
**作者**：Smith A, et al.
**摘要**：研究利用重组PKCε蛋白在体外分析其对肿瘤细胞迁移的影响，发现PKCε通过磷酸化RhoA并激活下游信号通路，促进细胞骨架重塑和侵袭能力。
---
2. **文献名称**：*Structural characterization of recombinant human PKCε kinase domain*
**作者**：Chen L, et al.
**摘要**：通过大肠杆菌表达系统纯化重组人源PKCε激酶结构域，结合X射线晶体学解析其三维结构，揭示了ATP结合口袋的关键氨基酸残基，为靶向抑制剂设计提供依据。
---
3. **文献名称**：*Recombinant PKCε protects against oxidative stress in neuronal cells*
**作者**：Wang Y, et al.
**摘要**：实验表明，外源性重组PKCε蛋白能通过激活Nrf2抗氧化通路，减少活性氧(ROS)积累，从而改善帕金森病模型中的神经元存活率。
---
**建议**：实际研究中可通过PubMed或Web of Science检索关键词“PKCε recombinant protein”或“recombinant PKCepsilon function”获取真实文献。
Protein kinase C epsilon (PKCε), a member of the protein kinase C (PKC) family, is a calcium-independent, phospholipid-dependent serine/threonine kinase classified under the novel PKC subfamily (nPKC). It plays critical roles in diverse cellular processes, including cell proliferation, apoptosis, differentiation, and stress responses. PKCε is distinct from other PKC isoforms due to its unique regulatory domain structure and activation mechanisms, primarily mediated by lipid second messengers like diacylglycerol (DAG) and phosphatidylserine. Its dysregulation has been implicated in cancer, neurodegenerative disorders, cardiovascular diseases, and metabolic syndromes, making it a key therapeutic target.
Recombinant PKCε proteins are engineered using heterologous expression systems (e.g., *E. coli*, insect cells, or mammalian cells*) to produce highly purified, functional kinase domains or full-length proteins for *in vitro* studies. These recombinant forms retain catalytic activity and substrate specificity, enabling researchers to investigate PKCε's signaling mechanisms, substrate interactions, and regulatory pathways. Tagged versions (e.g., His-tag, GST-tag) facilitate purification, detection, and protein-protein interaction assays.
Research applications include kinase activity assays, structural studies (e.g., X-ray crystallography), inhibitor screening for drug development, and elucidating its role in disease models. For instance, PKCε overexpression in cancer correlates with tumor invasiveness and chemoresistance, while its cardioprotective effects in ischemia-reperfusion injury highlight context-dependent functions. Recombinant PKCε tools have advanced the understanding of its dual roles in cell survival and stress adaptation, offering potential for targeted therapies. However, challenges remain in achieving post-translational modifications (e.g., phosphorylation) in certain expression systems, necessitating system-specific optimization.
×
